Boehringer Ingelheim

Accessibility Statement for Boehringer Ingelheim websites

Boehringer Ingelheim is committed to providing a website that is accessible to the widest possible audience, regardless of technology or ability. We are actively working to increase the accessibility and usability of our website and in doing so adhere to many of the available standards and guidelines. These guidelines explain how to make web content more accessible for people with disabilities. Conformance with these guidelines will help make the web more user friendly for all people. We are continually seeking out solutions that will bring all areas of the Site up to the same level of overall web accessibility.

Presentation of Content and Layout

There is a strict separation of content and layout via the proper use of HTML and CSS (Cascading Style Sheet). Layout tables are avoided where possible.

We are focusing on structuring items, making it possible to scan through a document and giving air to long texts. This includes:

  • chapter starting pages that show which content is provided within subchapters
  • consequent use of headlines, short introduction text on every webpage and sub headlines
  • tables and bullet list for helping readers
  • graphics for complex content

We try to offer a clear navigation structure that helps you to find the content you are looking for in an easy and quick way.

Links contain title attributes which describe content and make sense out of context.

The use of short sentences and paragraphs and multiple entry points to additional information sources e.g. via teaser elements and related content areas will make it easier to comprehend the content.

In the meantime, should you experience any difficulty in accessing the Boehringer Ingelheim website, please do not hesitate to contact us via communications.bra@boehringer-ingelheim.com.

 

If you live in the UK and you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the yellow card scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects, you can help provide more information on the safety of this medicine.

If you live in the Republic of Ireland and you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Health Products Regulatory Authority at www.hpra.ie or by email to medsafety@hpra.ie. By reporting side effects, you can help provide more information on the safety of this medicine.

This website has been developed by Boehringer Ingelheim and is intended for people with progressive pulmonary fibrosis who have been prescribed OFEV® (nintedanib).

This website is intended for people with progressive pulmonary fibrosis who have been prescribed treatment with OFEV® (nintedanib). OFEV® is used to treat idiopathic pulmonary fibrosis, or other chronic fibrosing interstitial lung diseases that are showing signs of progression and these diseases are referred to on this website collectively as ‘progressive pulmonary fibrosis’.

This website aims to provide you with information about your disease and how to manage your symptoms or the side effects of your treatment, as well as to give you details on holistic support available.

The information on this website has been developed to enhance, but not replace, the advice and help of your medical team. If you have any questions after reading this website, or any further concerns, always talk to your medical team – i.e., a nurse, doctor or pharmacist – they are here to help you.

You’ll also find more information about OFEV® in your Patient Information Leaflet (PIL), included with your OFEV® medication pack, or on www.medicines.org.uk/emc/product/7705/pil if you live in the United Kingdom, or on www.medicines.ie/medicines/ofev-150-mg-soft-capsules-33198/patient-info if you live in the Republic of Ireland.